Induction of Xenobiotic Receptors, Transporters, and Drug Metabolizing Enzymes by Oxycodone

Drug Metabolism and Disposition
2013.0

Abstract

Perturbations of the expression of transporters and drug-metabolizing enzymes (DMEs) by opioids can be the locus of deleterious drug-drug interactions (DDIs). Many transporters and DMEs are regulated by xenobiotic receptors [XRs; e.g., pregnane X receptor (PXR), constitutive androstane receptor (CAR), and Aryl hydrocarbon receptor (AhR)]; however, there is a paucity of information regarding the influence of opioids on XRs. The objective of this study was to determine the influence of oxycodone administration (15 mg/kg intraperitoneally twice daily for 8 days) on liver expression of XRs, transporters, and DMEs in rats. Microarray, quantitative real-time polymerase chain reaction and immunoblotting analyses were used to identify significantly regulated genes. Three XRs (e.g., PXR, CAR, and AhR), 27 transporters (e.g., ABCB1 and SLC22A8), and 19 DMEs (e.g., CYP2B2 and CYP3A1) were regulated (P < 0.05) with fold changes ranging from -46.3 to 17.1. Using MetaCore (computational platform), we identified a unique gene-network of transporters and DMEs assembled around PXR, CAR, and AhR. Therefore, a series of transactivation/translocation assays were conducted to determine whether the observed changes of transporters/DMEs are mediated by direct activation of PXR, CAR, or AhR by oxycodone or its major metabolites (noroxycodone and oxymorphone). Neither oxycodone nor its metabolites activated PXR, CAR, or AhR. Taken together, these findings identify a signature hepatic gene-network associated with repeated oxycodone administration in rats and demonstrate that oxycodone alters the expression of many transporters and DMEs (without direct activation of PXR, CAR, and AhR), which could lead to undesirable DDIs after coadministration of substrates of these transporters/DMEs with oxycodone.

Knowledge Graph

Similar Paper

Induction of Xenobiotic Receptors, Transporters, and Drug Metabolizing Enzymes by Oxycodone
Drug Metabolism and Disposition 2013.0
Induction Profile of Rat Organic Anion Transporting Polypeptide 2 (oatp2) by Prototypical Drug-Metabolizing Enzyme Inducers That Activate Gene Expression through Ligand-Activated Transcription Factor Pathways
The Journal of Pharmacology and Experimental Therapeutics 2002.0
Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation
The Journal of Pharmacology and Experimental Therapeutics 2003.0
Organ Distribution of Multidrug Resistance Proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and Hepatic Induction of Mrp3 by Constitutive Androstane Receptor Activators in Rats
The Journal of Pharmacology and Experimental Therapeutics 2002.0
Tissue Distribution and Chemical Induction of Multiple Drug Resistance Genes in Rats
Drug Metabolism and Disposition 2002.0
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Journal of Biological Chemistry 2001.0
Coinduction of MDR-1 Multidrug-Resistance and Cytochrome P-450 Genes in Rat Liver by Xenobiotics
JNCI Journal of the National Cancer Institute 1988.0
Identification of Clinically Used Drugs That Activate Pregnane X Receptors
Drug Metabolism and Disposition 2011.0
Opioids as Substrates and Inhibitors of the Genetically Highly Variable Organic Cation Transporter OCT1
Journal of Medicinal Chemistry 2019.0
INDUCTION OF ABCC3 (MRP3) BY PREGNANE X RECEPTOR ACTIVATORS
Drug Metabolism and Disposition 2003.0